Literature DB >> 17547831

Treatment of children with HIV infection.

Terry C Dixon1, Coleen K Cunningham.   

Abstract

The treatment of pediatric HIV infection has seen vast improvements in terms of better long-term suppression of HIV replication and subsequent improvements in the longevity and quality of life in children. This has been realized, in part, by development of newer antiretroviral medications, better knowledge about the pharmaco-kinetics of these drugs in children, and improved insight on drug toxicities in children. This review will discuss some of the newer agents that may be available for children in the near future, in addition to new pharmacokinetic and toxicity data that are specific to the pediatric patient. New information on key vaccines that should be administered to children with HIV infection is also discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17547831     DOI: 10.1007/s11904-007-0014-9

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.495


  30 in total

1.  Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.

Authors:  Mark Nelson; Keikawus Arastéh; Bonaventura Clotet; David A Cooper; Keith Henry; Christine Katlama; Jacob P Lalezari; Adriano Lazzarin; Julio S G Montaner; Mary O'Hearn; Peter J Piliero; Jacques Reynes; Benoit Trottier; Sharon L Walmsley; Calvin Cohen; Joseph J Eron; Daniel R Kuritzkes; Joep Lange; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Neil E Buss; Lucille Donatacci; Cynthia Wat; Lynn Smiley; Martin Wilkinson; Adeline Valentine; Denise Guimaraes; Ralph Demasi; Jain Chung; Miklos P Salgo
Journal:  J Acquir Immune Defic Syndr       Date:  2005-12-01       Impact factor: 3.731

2.  Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment.

Authors:  Grace M Lee; Steven L Gortmaker; Kenneth McIntosh; Michael D Hughes; James M Oleske
Journal:  Pediatrics       Date:  2006-02       Impact factor: 7.124

3.  Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.

Authors:  Raffaella Rosso; Antonio Di Biagio; Chiara Dentone; Guido Castelli Gattinara; Alessandra Maria Martino; Alessandra Viganò; Marzia Merlo; Carlo Giaquinto; Osvalda Rampon; Matteo Bassetti; Giorgio Gatti; Claudio Viscoli
Journal:  J Antimicrob Chemother       Date:  2006-04-10       Impact factor: 5.790

4.  Incidence of opportunistic and other infections in HIV-infected children in the HAART era.

Authors:  Philimon Gona; Russell B Van Dyke; Paige L Williams; Wayne M Dankner; Miriam C Chernoff; Sharon A Nachman; George R Seage
Journal:  JAMA       Date:  2006-07-19       Impact factor: 56.272

5.  Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.

Authors:  Deborah S Storm; Mary G Boland; Steven L Gortmaker; Yan He; Joan Skurnick; Lois Howland; James M Oleske
Journal:  Pediatrics       Date:  2005-01-03       Impact factor: 7.124

6.  Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children.

Authors:  Joseph A Church; Coleen Cunningham; Michael Hughes; Paul Palumbo; Lynne M Mofenson; Patricia Delora; Elizabeth Smith; Andrew Wiznia; Lynette Purdue; Elizabeth Hawkins; Prakash Sista
Journal:  Pediatr Infect Dis J       Date:  2002-07       Impact factor: 2.129

Review 7.  Human papillomavirus infection and disease in HIV-infected individuals.

Authors:  Michael E Hagensee; Jennifer E Cameron; Janet E Leigh; Rebecca A Clark
Journal:  Am J Med Sci       Date:  2004-07       Impact factor: 2.378

8.  Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.

Authors:  Ross E McKinney; John Rodman; Chengcheng Hu; Paula Britto; Michael Hughes; Mary Elizabeth Smith; Leslie K Serchuck; Joyce Kraimer; Alberto A Ortiz; Patricia Flynn; Ram Yogev; Stephen Spector; Linda Draper; Paul Tran; Melissa Scites; Ruth Dickover; Adriana Weinberg; Coleen Cunningham; Elaine Abrams; M Robert Blum; Gregory E Chittick; Laurie Reynolds; Mobeen Rathore
Journal:  Pediatrics       Date:  2007-07-23       Impact factor: 7.124

9.  Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).

Authors:  Alina Bergshoeff; David Burger; Corrien Verweij; Laura Farrelly; Jacquie Flynn; Marthe Le Prevost; Sarah Walker; Vas Novelli; Hermione Lyall; Saye Khoo; Di Gibb
Journal:  Antivir Ther       Date:  2005

10.  Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.

Authors:  Marthe LePrevost; Hannah Green; Jacquie Flynn; Stephen Head; Margaret Clapson; Hermione Lyall; Vas Novelli; Laura Farrelly; A Sarah Walker; David M Burger; Diana M Gibb
Journal:  Pediatr Infect Dis J       Date:  2006-06       Impact factor: 2.129

View more
  2 in total

1.  A pilot study comparing traumatic stress symptoms by child and parent report across pediatric chronic illness groups.

Authors:  Lisa M Ingerski; Kimberly Shaw; Wendy N Gray; David M Janicke
Journal:  J Dev Behav Pediatr       Date:  2010 Nov-Dec       Impact factor: 2.225

Review 2.  The rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies.

Authors:  Kristina Abel
Journal:  Curr HIV Res       Date:  2009-01       Impact factor: 1.581

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.